City of Hope | Strategic Alliance Partners

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

The organizations join forces to become one of the largest cancer research and treatment organizations in the country.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

Cancer Treatment Centers of America's comprehensive cancer centers in Chicago and Atlanta earned the 2021 Guardian of Excellence Award from Press Ganey as top performers in patient experience.

It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.

Katherine Poruk, MD, a board-certified and fellowship-trained surgical oncologist and researcher, is the latest addition to the Cancer Treatment Centers of America®, Atlanta, physician team.

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Corepoint Integration Engine chosen to Streamline Connectivity Across Care Teams, Affiliate Networks, and Cancer Community, Extending Access to World-class Care for Patients Everywhere.

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.